Replibio: Acquires 30% equity of its holding subsidiary for 65.865 million yuan.

Ruipu Bioscience announced that on June 10, 2026, the company signed a "Equity Transfer Agreement" with Ruipai Pet Hospital and Zhongrui Supply Chain, intending to acquire 30.00% of Zhongrui Supply Chain's equity held by Ruipai Pet Hospital for 65.865 million yuan. After the completion of the transaction, the company will hold 86.00% of Zhongrui Supply Chain's equity. This transaction constitutes a related party transaction, does not constitute a major asset restructuring, and does not require submission to the company's shareholder meeting for approval. Due to external factors, there may be fluctuations in the future operating performance of Zhongrui Supply Chain.